0K9E Stock Overview Engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for Novartis Historical stock prices Current Share Price CHF 97.49 52 Week High CHF 120.72 52 Week Low CHF 92.39 Beta 0.51 1 Month Change -5.97% 3 Month Change -16.20% 1 Year Change -1.27% 3 Year Change 12.47% 5 Year Change 2.79% Change since IPO 3.81%
Recent News & Updates
Novartis Inc. Announces Results from an Updated Analysis of the Pivotal Phase III Natalee Trial of Kisqali®? (ribociclib) Dec 12
Novartis Announces Positive, Long-Term Results from the Pivotal Phase III ASC4FIRST Trial with Scemblix (asciminib) Dec 09
Novartis Announces Positive Topline Results from APPULSE-PNH, a Phase IIIB Study Evaluating the Efficacy and Safety of Two-Daily Oral Monotherapy Fabhalta Dec 06
Novartis Kisqali Receives European Commission Approval in A Broad Population of Patients with HR+/HER2- Early Breast Cancer at High Risk of Recurrence Nov 27 Novartis AG (SWX:NOVN) acquired Kate Therapeutics, Inc. in a transaction valued at $1.1 billion. Nov 22
Novartis' Scemblix® Receives Approval from US Food and Drug Administration Oct 30 See more updates
Novartis Inc. Announces Results from an Updated Analysis of the Pivotal Phase III Natalee Trial of Kisqali®? (ribociclib) Dec 12
Novartis Announces Positive, Long-Term Results from the Pivotal Phase III ASC4FIRST Trial with Scemblix (asciminib) Dec 09
Novartis Announces Positive Topline Results from APPULSE-PNH, a Phase IIIB Study Evaluating the Efficacy and Safety of Two-Daily Oral Monotherapy Fabhalta Dec 06
Novartis Kisqali Receives European Commission Approval in A Broad Population of Patients with HR+/HER2- Early Breast Cancer at High Risk of Recurrence Nov 27 Novartis AG (SWX:NOVN) acquired Kate Therapeutics, Inc. in a transaction valued at $1.1 billion. Nov 22
Novartis' Scemblix® Receives Approval from US Food and Drug Administration Oct 30
Novartis Raises Earnings Guidance for the Fiscal Year 2024 Oct 29
Novartis AG, Annual General Meeting, Mar 07, 2025 Oct 16 Alkem Labs Reportedly in Talks to Acquire Novartis India from Its Swiss Parent Novartis Announces Positive Topline Results from Twice-Yearly Leqvio (Inclisiran) in the Phase III V-Mono Study Aug 28
Siemens Healthineers Offers to Buy Novartis Molecular Imaging Business Aug 26
Novartis Receives FDA Accelerated Approval for Fabhalta (iptacopan) Aug 08
Novartis AG to Report Q4, 2024 Results on Jan 31, 2025 Jul 18 Novartis AG Presents Latest Phase III Fabhalta®? (iptacopan) Data in C3 Glomerulopathy (C3G)
Novartis AG (SWX:NOVN) entered into an agreement to acquire Mariana Oncology, Inc. from Atlas Venture L.P., Access Biotechnology, RA Capital Management, L.P., Deep Track Capital, LP, Forbion Capital Partners B.V. and others for $1.8 billion. May 03
Novartis and Medicines for Malaria Venture Announce Positive Efficacy and Safety Data for A Novel Treatment for Babies Apr 24 Novartis AG Revise Earnings Guidance for the Year 2024 Apr 23
Novartis' Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthritis Treatment, While Pending Launch of UCB’s Bimzelx Poised to Further Disrupt the Market Apr 18
Novartis Presents Results from Pre-Specified Interim Analysis of the Phase III APPLAUSE-IgAN study of Fabhalta Apr 17
Novartis Fabhalta Receives Positive CHMP Opinion as First Oral Monotherapy for Adult Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Mar 23 Novartis AG (SWX:NOVN) acquired IFM Due, Inc. from IFM Therapeutics, LLC for approximately $840 million. Mar 13
Dr. Reddy's Laboratories Denies in Race to Acquire Novartis' Stake in Novartis India Feb 20
Dr Reddy's Reportedly May Join Race to Acquire Novartis' India Arm Feb 19
Novartis AG Announces FDA Approves Xolair® (Omalizumab) as First and Only Medicine for Children and Adults with One or More Food Allergies Feb 17
Novartis Reportedly in Lead to Acquire MorphoSys Feb 06
Novartis AG Provides Earnings Guidance for the Year 2024 Novartis AG to Report Q1, 2024 Results on Apr 23, 2024 Novartis AG Presents Data from the Phase III NETTER-2 Trial Jan 20
Novartis Pursuit of Cytokinetics Reportedly Cools Jan 12 Novartis Reportedly in Advanced Talks to Buy Cytokinetics Jan 09
Novartis AG Announces Positive Results from the Primary Analysis of ASC4FIRST Novartis AG (SWX:NOVN) acquired SanReno Therapeutics from Pivotal bioVenture Partners China, Versant Venture Management, LLC, Samsara BioCapital LLC, Frazier Healthcare Partners managed by Frazier Management, L.L.C. and Frazier Life Sciences Management, LP. Jan 05
Novartis Investigational Iptacopan Phase III Study Demonstrates Clinically Meaningful and Statistically Significant Proteinuria Reduction in Patients with C3 Glomerulopathy (C3G) Dec 11 Latest Novartis Kisqali(R) Natalee Analysis Reinforces 25% Reduction in Risk of Recurrence Across Broad Population of Patients with Early Breast Cancer Dec 08
Novartis Receives FDA Approval for Fabhalta (iptacopan) Offering Superior Hemoglobin Improvement in the Absence of Transfusions as the First Oral Monotherapy for Adults with PNH Dec 06
Novartis AG to Report Q4, 2023 Results on Jan 31, 2024
Novartis Announces New Positive Data from the Phase III REMIX-1 and REMIX-2 Studies Investigating Remibrutinib Nov 11
Novartis Announces US Food and Drug Administration Approves Cosentyx® to Treat Moderate to Severe Hidradenitis Suppurativa in Adults Nov 01 Novartis Announces Positive Topline Results from the Interim Analysis of the Ongoing Pivotal Phase III ALIGN Study Oct 31
Novartis AG Announces Impairment Charges for the Third Quarter of 2023 Oct 25
Novartis AG Raises Earnings Guidance for the Fiscal Year 2023
Novartis Kisqali Natalee Analysis Confirms Consistent Reduction in Risk of Recurrence Across Key Sub Groups of Patients with Early Breast Cancer Oct 21 FDA Approves Novartis Cosentyx® as First Intravenous (Iv) Formulation Interleukin-17A Antagonist for Rheumatic Diseases Oct 08
Novartis to Present New Oncology Data at ESMO 2023 Demonstrating Practice-Changing Innovation in Advanced Prostate and Early Breast Cancer Oct 07
Novartis AG completed the Spin-Off of Sandoz Group AG (SWX:SDZ).
Bausch & Lomb Ireland completed the acquisition of ophthalmology assets of Novartis AG from Novartis AG for $2.5 billion. Oct 01
Sandoz, Novartis Division, Receives European Commission Approval for Tyruko (Natalizumab), First and Only Biosimilar for Multiple Sclerosis in Europe Sep 26 Shareholder Returns 0K9E GB Pharmaceuticals GB Market 7D -1.0% -1.7% -2.6% 1Y -1.3% -3.5% 2.4%
See full shareholder returns
Return vs Market: 0K9E underperformed the UK Market which returned 2.4% over the past year.
Price Volatility Is 0K9E's price volatile compared to industry and market? 0K9E volatility 0K9E Average Weekly Movement 2.2% Pharmaceuticals Industry Average Movement 6.1% Market Average Movement 4.8% 10% most volatile stocks in GB Market 10.7% 10% least volatile stocks in GB Market 2.6%
Stable Share Price: 0K9E has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0K9E's weekly volatility (2%) has been stable over the past year.
About the Company Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors.
Show more Novartis AG Fundamentals Summary How do Novartis's earnings and revenue compare to its market cap? 0K9E fundamental statistics Market cap US$194.15b Earnings (TTM ) US$11.76b Revenue (TTM ) US$49.94b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0K9E income statement (TTM ) Revenue US$49.94b Cost of Revenue US$12.07b Gross Profit US$37.87b Other Expenses US$26.11b Earnings US$11.76b
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Jan 31, 2025
Earnings per share (EPS) 5.88 Gross Margin 75.83% Net Profit Margin 23.55% Debt/Equity Ratio 69.8%
How did 0K9E perform over the long term?
See historical performance and comparison Dividends
3.7% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/21 11:13 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Novartis AG is covered by 68 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Kamla Singh AlphaValue John Eade Argus Research Company Fabrizio Spagna Axia Financial Research
Show 65 more analysts 
